Highest development stage: Approved by FDA in 2024

Development status: Approved

Gram-negative activity

Combination therapy

Mechanism of Action/Target pathogen: Active against <i>Enterobacteriaceae</i>; indicated for urinary tract infection, hospital and ventilation acquired bacterial pneumoniae, and complicated intraabdominal infection